This grant funds consortia of procurers to collaboratively develop affordable, innovative cancer technologies, medical devices, or medicines. Projects must clinically validate and pilot solutions in at least five EU or Associated countries. The initiative emphasizes end-user engagement, including patients and healthcare providers, to ensure solutions meet real needs. It supports the commercialization of innovations that improve health outcomes and cost-efficiency in cancer care.
Eligible applicants include consortia of procurers from EU Member States and Associated Countries meeting general admissibility, financial, and operational capacity conditions. Specific eligibility and evaluation criteria are detailed in the Horizon Europe Work Programme General Annexes.
